The results of this quantitative analysis suggest that a biomarker panel composed of plasma EV CD59 and TSPAN9 (tetraspanin 9) can efficiently distinguish CRC patients from HCs with an AUC (area under the receiver operating characteristic [ROC] curve) value of 0.98. This evidence concerns the gene CD59 and colorectal carcinoma.